Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

被引：5
|
作者：
Buecklein, Veit
Blumenberg, Viktoria
Ackermann, Josephine
Schmidt, Christian
Rejeski, Kai
Mueller, Niklas
Reischer, Anna
von Baumgarten, Louisa
Schoeberl, Florian
Humpe, Andreas
von Bergwelt, Michael
Subklewe, Marion
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Hashmi, Ayesha
    Hamilton, Mark P.
    Jensen, Alexandria
    Goyal, Anmol
    Marar, Mallika
    Lee, Caroline
    Ananth, Snegha
    Sahaf, Bita
    Mallampet, Jayasindhu
    Ehlinger, Zachary
    Syal, Shriya
    Patil, Sunita
    Guo, Henry
    Smith, Melody
    Weng, Wen-Kai
    Frank, Matthew J.
    Binkley, Michael S.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [32] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
    Locke, Frederick Lundry
    Ghobadi, Armin
    Jacobson, Caron A.
    Jacobsen, Eric D.
    Miklos, David Bernard
    Lekakis, Lazaros J.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Lin, Yi
    Siddiqi, Tanya
    Deol, Abhinav
    Reagan, Patrick Michael
    Farooq, Umar
    Bot, Adrian
    Jiang, Yizhou
    Rossi, John M.
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.
    Locke, Frederick L.
    Siddiqi, Tanya
    Jacobson, Caron Alyce
    Ghobadi, Armin
    Ahmed, Sairah
    Miklos, David Bernard
    Perales, Miguel-Angel
    Munoz, Javier
    Logan, Brent
    Hu, Zhen-Huan
    Miao, Harry H.
    Singh, Kanwarjit
    Shah, Jina
    Xu, Hairong
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).
    Jacobson, Caron A.
    Locke, Frederick Lundry
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Ahmed, Sairah
    Ghobadi, Armin
    Miklos, David Bernard
    Lin, Yi
    Perales, Miguel-Angel
    Lunning, Matthew Alexander
    Herr, Megan
    Hill, Brian T.
    Ganguly, Siddhartha
    Dong, Hua
    Nikiforow, Sarah
    Xie, Jing
    Xu, Hairong
    Hooper, Michele
    Kawashima, Jun
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
    Locke, F. L.
    Bartlett, N. L.
    Jacobson, C. A.
    Oluwole, O. O.
    Munoz, J.
    Lekakis, L. J.
    Topp, M. S.
    Avivi, I
    Kim, J. J.
    Chu, R.
    Zheng, L.
    Rossi, J. M.
    Bot, A.
    Neelapu, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
  • [36] Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
    Jacobson, Caron
    Locke, Frederick L.
    Ghobadi, Armin
    Miklos, David B.
    Lekakis, Lazaros J.
    Oluwole, Olalekan O.
    Lin, Yi
    Braunschweig, Ira
    Hill, Brian T.
    Timmerman, John M.
    Deol, Abhinav
    Reagan, Patrick M.
    Stiff, Patrick J.
    Flinn, Ian W.
    Farooq, Umar
    Goy, Andre H.
    McSweeney, Peter A.
    Munoz, Javier
    Siddiqi, Tanya
    Rossi, John M.
    Bot, Adrian
    Zheng, Lianqing
    Vezan, Remus
    Bashir, Zahid
    Kim, Jenny J.
    Chu, Rong
    Neelapu, Sattva S.
    BLOOD, 2020, 136
  • [37] Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety and Efficacy of ZUMA-1
    Neelapu, S. S.
    Ghobadi, A.
    Jacobson, C. A.
    Miklos, D. B.
    Lekakis, L. J.
    Oluwole, O. O.
    Lin, Y.
    Braunschweig, I.
    Hill, B. T.
    Timmerman, J. M.
    Deol, A.
    Reagan, P. M.
    Stiff, P.
    Flinn, I. W.
    Farooq, U.
    Goy, A.
    McSweeney, P. A.
    Munoz, J.
    Siddiqi, T.
    Chavez, J. C.
    Herrera, A. F.
    Xue, A.
    Jiang, Y.
    Bot, A.
    Rossi, J. M.
    Kim, J. J.
    Go, W. Y.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 26 - 27
  • [38] Single-Center Experience of Axicabtagene Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
    Melody, Megan
    Rahman, Zaid Abdel
    Ernesto, Ayala
    Gannon, Nicole
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Foran, James
    Dabaja, Mohamed Kharfan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S267 - S268
  • [39] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91
  • [40] CLINICAL PREDICTORS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS
    Sanderson, R.
    Munoz, J.
    Wang, Y.
    Kanters, S.
    Limbrick-Oldfield, E.
    Miao, H.
    Spooner, C.
    Baro, E.
    Xu, H.
    Jacobson, C.
    VALUE IN HEALTH, 2022, 25 (12) : S47 - S48
12345